Compare Amylx Pharmaceuticals Inc (AMLX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Tapestry, Inc. trades at $140.32 (market cap $28.43B). The key difference: Tapestry, Inc. is far larger — about 14.4× Amylx Pharmaceuticals Inc's market cap, and Tapestry, Inc. pays a 1.14% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TPR | |
|---|---|---|
Market Cap | $1.98B | $28.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $160.49 |
52-Week Low | $7.64 | $95.69 |
Enterprise Value | $1.70B | $31.29B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
TPR trades at $140.73, up 0.57% today, with a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.24. Valuation ratios are elevated (P/E 42.91, P/B 41.67), though profitability metrics like a 76.18% gross margin and 55.74% ROE remain robust. Recent news highlights digital growth and Gen Z engagement, with a $0.40 dividend paid in June 2026.
The outlook is mixed: bullish analyst consensus ($184.14 price target, 75.61% buy ratings) contrasts with technical bearishness and a high debt load. Key risks include sensitivity to consumer spending and execution of growth initiatives. Upside hinges on sustained earnings beats and margin expansion, while debt management and competitive pressures pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
